Mark McDonough

Mark McDonough

Independent Director, Vesica Health

Mr. McDonough is a seasoned leader in the genomics and diagnostics industries, renowned for his ability to drive growth and innovation in high-growth companies.

Formerly the CEO and Board member of ChromaCode, Inc, Mr. McDonough spearheaded the utilization of their High-Definition PCR (HDPCR™) platform, enabling comprehensive, fast, and cost-effective testing solutions in genomics multiplexing. Prior to his tenure at ChromaCode, he served as CEO of PierianDx, where he successfully secured significant funding and orchestrated a prosperous exit to Summa Equity, leading to the formation of Velsera. Mr. McDonough has held pivotal leadership roles as President, CEO, and Board member for Immunis.AI, a pre-commercial liquid biopsy platform company, as well as at CombiMatrix, a leader in high-complexity reproductive health testing. Notably, he guided CombiMatrix through a successful turnaround, culminating in its sale in November 2017.

With a distinguished background in high-growth diagnostic companies, including US LABS (acquired by LabCorp) and Ventana Medical Systems (acquired by Roche), Mr. McDonough brings a wealth of experience and expertise to his roles. Additionally, he is a proud former Naval Officer, having served as a Navigator and Communications Officer on the USS FLETCHER (DD 992).